Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice
Resumen: Purpose: Trastuzumab has proven to improve the prognosis of HER2-positive breast cancer, but the information available about its administration for small tumors is still limited. Therefore, we assessed the use of adjuvant regimens with trastuzumab for the treatment of small HER2-positive breast cancer in routine clinical practice. Methods: This observational study was conducted in patients with HER2-positive breast adenocarcinoma =1.5 cm who received trastuzumab-based adjuvant treatment in clinical practice. Clinical/histopathological data were retrieved from patients’ medical charts. Results: A total of 101 evaluable patients were enrolled (median age range], 56.7 49.0–64.8] years//ECOG 0, 98.0 %//ductal carcinoma, 88.1 %//lymph nodes N0, 79.2 %). Only five (5.0 %) patients received neoadjuvant treatment, while all patients underwent tumor surgery. Adjuvant trastuzumab was administered at a mean (±SD) dose of 5.9 ± 1.5 mg/kg/cycle, and mostly in a three-weekly schedule (89 89.0 %] patients). The most frequent adjuvant therapy used with trastuzumab was chemotherapy (87 86.1 %] patients), followed by radiotherapy (63 62.4 %] patients) and hormone therapy (52 51.5 %] patients). Chemotherapy regimens mainly included doxorubicin, cyclophosphamide and paclitaxel/docetaxel (n = 30), docetaxel and cyclophosphamide (n = 15), docetaxel and carboplatin (n = 13). Hormone therapy mainly included letrozole (n = 17) and tamoxifen (n = 17). Nine (8.9 %) patients reported trastuzumab-related adverse events//only one allergic reaction reached grade 3 toxicity. Conclusion: This study shows that trastuzumab-based adjuvant treatment of small HER2-positive breast cancer is mostly based on chemotherapy—mainly paclitaxel/docetaxel. Adjuvant administration of trastuzumab for small HER2-positive breast cancer seems to be similar to that used for larger tumors.
Idioma: Inglés
DOI: 10.1007/s12094-015-1316-9
Año: 2015
Publicado en: Clinical and Translational Oncology 17, 11 (2015), 862-869
ISSN: 1699-048X

Factor impacto JCR: 2.075 (2015)
Categ. JCR: ONCOLOGY rank: 153 / 213 = 0.718 (2015) - Q3 - T3
Factor impacto SCIMAGO:

Tipo y forma: Article (Published version)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material.

Exportado de SIDERAL (2020-01-03-14:00:20)

Este artículo se encuentra en las siguientes colecciones:

 Record created 2016-01-25, last modified 2020-01-03

Versión publicada:
Rate this document:

Rate this document:
(Not yet reviewed)